Dr Riess on Sequencing Considerations for KRAS and BRAF Inhibitors in NSCLC
Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.
Related Articles
Encorafenib Triplet Could Address Poor Outcomes With Immunotherapy in BRAF V600âMutant Melanoma With Brain Metastases
Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600âmutant melanoma with symptomatic brain metastases.
Five Under 5: Top Oncology Videos for the Week of 8/10
The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.
OncLiveâs July EMA Regulatory Recap: Key EU Approvals in Oncology
Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.
The OncFive: Top Oncology Articles for the Week of 8/10
Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.
Casdatifan Plus Cabozantinib Shows Meaningful Clinical Activity in Pretreated ccRCC
Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.
Zidesamtinib Is Set to Overcome the Limitations of Current ROS1 TKIs in in ROS1+ NSCLC
Joshua K. Sabari, MD, discusses the design of the phase 1/2 ARROS-1 study, as well as key efficacy data with zidesamtinib in ROS1 fusionâpositive NSCLC.
Dr DeAngelo on Challenges With Utilizing Pediatric-Inspired Regimens in Adult and AYA ALL
Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyperâCVAD in adult and AYA patients with ALL.
Neoadjuvant Olaparib Plus Carboplatin Reduces Residual Cancer Burden in BRCA1/2-Mutated, HRD+ TNBC
Neoadjuvant olaparib plus carboplatin led to a high RCB 0/1 rate in BRCA1/2-mutated, HRD+ TNBC.
New Treatment Eliminates Bladder Cancer in 82% of Patients
TAR-200 was found to be highly effective in treating select patients with bladder cancer whose tumors were previously unresponsive to therapy.
Novel Lipo-MITâBased Triplet Drives Responses in R/R Myeloma
Bortezomib plus mitoxantrone hydrochloride liposome and dexamethasone produced responses with manageable safety in relapsed/refractory myeloma